Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101 - Seite 2

Kinases play a key role in regulating most cellular functions, such as proliferation, cell cycle progression, metabolism, survival or apoptosis, repair of damaged DNA, motility, and response to the microenvironment. This means that targeting kinases represents a major opportunity in over 400 diseases.

Philippe GENNE, Co-founder, Chairman and CEO of Oncodesign Precision Medicine, said: "This €5.6 million grant is particularly significant for the company: the successful development of OPM-101 is key to our growth. It comes at a time when, like national and international biotechs, financing is more difficult to obtain from investors, particularly on the stock market. This project is perfectly in line with our strategy and should enable OPM-101 to complete its phase 2a trial in IIUC patients under the best possible conditions and without losing any time. This support from the French government, as part of the France 2030 program, is the fruit of an in-depth assessment of the project and provides further confirmation of the interest in this drug candidate, which represents a breakthrough innovation in the treatment of patients suffering from severe colitis. We are particularly proud and grateful for this national recognition, which follows other recent successes with the COMETE and ANIMUS projects. It proves that our country is giving itself the means to build a strong healthcare industry for tomorrow".

Jan HOFLACK, Co-Founder and Chief Medical Officer of Oncodesign Precision Medicine added: "OPM-101, a RIPK2 inhibitor molecule derived from our breakthrough Nanocyclix technology, continues its path towards proof of efficiency in patients after its phase 1 trial, which demonstrated very interesting properties in terms of pharmacokinetics, safety profile and pharmacodynamics in healthy volunteers. Our product is positioned in major markets and has the potential to bring real benefits to patients suffering from multiple types of colitis. This potential has been well understood by government experts in the context of France 2030. OPM-101 has the potential to become a "First-in-Class" and a "Best-in-Class" molecule, so it was essential for us not to waste any time. Our RIPK2 inhibitors also have the potential to become a real franchise, with promising results obtained in immuno-oncology with our series of molecules."